Rasmussen encephalitis is a rare neurological condition that causes ongoing inflammation in one half of the brain, leading to frequent seizures and progressive decline in mental and physical abilities. While there is no cure, various treatment approaches aim to control seizures, slow disease progression, and improve the quality of life for affected children and their families.

When the Brain Becomes Its Own Target: Understanding Treatment Goals

Managing Rasmussen encephalitis requires a comprehensive approach that focuses on multiple treatment goals. The primary aim is to control the frequent and often relentless seizures that characterize this condition. These seizures can occur every few seconds or minutes in some patients, severely disrupting daily life and causing additional brain damage over time. Beyond seizure control, treatment strategies work to slow the progressive inflammation that damages brain tissue, preserve as much neurological function as possible, and support the overall quality of life for both patients and their families.^[1]

Treatment decisions depend heavily on the stage of the disease and individual patient characteristics. Rasmussen encephalitis typically progresses through three distinct phases. During the early prodromal stage, seizures may occur infrequently and children often show no obvious neurological problems. The acute stage brings more frequent seizures and visible brain shrinkage on imaging scans, along with developing weakness, vision changes, or speech difficulties. Finally, the residual stage sees fewer seizures but leaves behind significant, permanent neurological damage. The timing and type of treatment must be carefully matched to which stage the patient has reached.^[6]

Medical societies have established standard treatment protocols based on decades of clinical experience with this rare condition. However, because Rasmussen encephalitis affects only about two out of every 10 million people, there is ongoing research into new therapeutic approaches. Clinical trials are exploring innovative treatments that may offer hope for better outcomes, particularly for children who do not respond well to currently available options.^[1][2]

Traditional Approaches: Standard Treatment Methods

The standard treatment approach for Rasmussen encephalitis begins with anti-seizure medications, though these drugs face significant limitations in this particular condition. Most children with Rasmussen encephalitis develop what doctors call intractable seizures, meaning the seizures cannot be completely controlled by medication alone. Despite this challenge, neurologists typically start with anti-seizure drugs as a first-line approach, adjusting dosages and trying different combinations in an attempt to reduce seizure frequency and severity.^[1][8]

When standard anti-seizure medications prove insufficient, doctors may turn to immunosuppressive therapies. These treatments work by dampening the immune system’s attack on brain tissue, which is believed to be the underlying cause of the inflammation. Steroids represent one category of immunosuppressive medication used in Rasmussen encephalitis. These powerful anti-inflammatory drugs can sometimes help reduce brain inflammation, though their effectiveness varies from patient to patient. Long-term steroid use carries risks including weight gain, mood changes, weakened bones, and increased susceptibility to infections.^[7]

Another immunosuppressive approach involves intravenous immunoglobulin, often abbreviated as IVIG. This treatment consists of antibodies collected from healthy blood donors and given through an IV infusion. The goal is to modify the immune system’s abnormal response that drives the brain inflammation. Some patients receive IVIG treatments regularly over extended periods. While IVIG is generally considered safer than long-term steroids, it requires repeated hospital visits for infusions and may cause side effects such as headaches, fever, or allergic reactions.^[7]

The duration of medical therapy varies considerably depending on how well a patient responds and whether the disease continues to progress. Some children may receive anti-seizure medications and immunosuppressive treatments for months or even years. Throughout this time, doctors closely monitor both the effectiveness of treatment and any emerging side effects. Blood tests, brain imaging scans, and regular neurological examinations help guide ongoing treatment decisions.^[2]

For many patients with Rasmussen encephalitis, medical treatments alone cannot adequately control seizures or prevent progressive brain damage. In these cases, surgery becomes the most definitive treatment option. Hemispherectomy is a surgical procedure that involves either removing or disconnecting the affected hemisphere of the brain from the healthy side. While this may sound drastic, the procedure can be life-changing for appropriate candidates. By preventing seizure activity from the damaged hemisphere from affecting the rest of the brain, hemispherectomy often achieves complete seizure control.^[7]

Modern surgical techniques for hemispherectomy have evolved to be less invasive than in the past. Rather than physically removing large amounts of brain tissue, surgeons now typically perform what is called a functional hemispherectomy or hemispherotomy. This approach disconnects the affected hemisphere by cutting key nerve pathways while leaving most of the tissue in place. This modification reduces the risk of complications such as excessive bleeding while achieving the same seizure control benefits.^[7]

The decision to proceed with hemispherectomy involves carefully weighing potential benefits against inevitable consequences. Because the surgery affects an entire hemisphere, patients will have permanent changes in function. These typically include weakness or paralysis on one side of the body opposite to the surgical side. Vision loss affecting half of each eye’s visual field is also expected. If the dominant hemisphere for language is affected, speech and language abilities will be impacted. However, children’s brains have remarkable plasticity, meaning the healthy hemisphere can sometimes take over some functions from the damaged side, especially if surgery is performed at a younger age.^[1][6]

Recovery from hemispherectomy requires intensive rehabilitation. Physical therapy helps patients regain as much mobility as possible and learn to adapt to weakness on one side of the body. Occupational therapy focuses on relearning daily activities and developing compensatory strategies. Speech therapy addresses language difficulties when applicable. This rehabilitation process typically continues for many months after surgery and plays a crucial role in helping patients achieve their maximum potential despite permanent neurological changes.^[15]

Exploring New Horizons: Treatment in Clinical Trials

Because standard treatments have significant limitations, researchers continue to investigate innovative approaches for Rasmussen encephalitis through clinical trials. These studies explore various strategies based on growing understanding of the disease’s underlying mechanisms. Scientists now believe that Rasmussen encephalitis is driven primarily by cytotoxic T-cells, a type of immune cell that mistakenly attacks the brain’s neurons and supporting cells. This insight has opened new avenues for targeted therapies.^[3][4]

One area of clinical research focuses on more specific immunological interventions. Unlike broad immunosuppressive drugs like steroids, these newer approaches attempt to selectively target the abnormal immune response while preserving the rest of the immune system’s protective functions. Researchers are investigating medications that specifically block T-cell activation or prevent these cells from entering brain tissue. Early-phase clinical trials, known as Phase I studies, focus primarily on establishing the safety of these approaches in humans. If a treatment proves safe, Phase II trials examine whether it actually reduces seizures or slows disease progression.^[3]

Some clinical trials are examining the role of autoantibodies in Rasmussen encephalitis. While T-cells appear to be the main drivers of brain damage, researchers have also found antibodies in some patients that may contribute to the disease process. These antibodies target specific proteins on brain cells, potentially causing additional injury. Experimental treatments aimed at removing these harmful antibodies from the bloodstream, such as plasma exchange or specialized filtering procedures, are being studied. These therapies might work alongside other treatments to more comprehensively address the immune dysfunction.^[3]

Another promising research direction involves understanding why the inflammation in Rasmussen encephalitis remains confined to one hemisphere. Scientists are studying the molecular pathways that allow immune cells to infiltrate and damage brain tissue in such a localized pattern. This research may identify specific molecules or receptors that could be targeted with new drugs. For example, treatments that block the signals allowing immune cells to cross from the bloodstream into brain tissue could potentially prevent further damage.^[4]

Clinical trials for rare diseases like Rasmussen encephalitis face unique challenges. With only about two new cases identified per year even at large epilepsy centers, recruiting enough patients to definitively prove a treatment’s effectiveness can take many years. Trials may be conducted across multiple centers in different countries to reach sufficient patient numbers. Locations for Rasmussen encephalitis studies have included specialized epilepsy centers in the United States, Europe, and other regions with advanced neurological care facilities.^[2][3]

Patient eligibility for clinical trials typically depends on several factors. Most studies require confirmation of the Rasmussen encephalitis diagnosis through specific criteria based on seizure patterns, brain imaging findings, and sometimes tissue analysis. The disease stage matters as well—some trials may focus on patients in the early, highly active phase, while others might include those with established, stable disease. Age restrictions vary by study, though many focus on children since they represent the majority of cases. Previous treatments received may also affect eligibility, as researchers want to avoid confounding factors that could make results difficult to interpret.^[6]

Preliminary results from some immunotherapy trials have shown mixed outcomes. In certain patients, aggressive immunosuppressive protocols initiated early in the disease course appeared to slow progression and reduce seizure frequency. However, others showed minimal response, and the inflammation continued despite treatment. These variable results underscore the complexity of the condition and suggest that different patients may have different underlying immune triggers. Ongoing research aims to identify biomarkers that could predict which patients are most likely to benefit from specific immunological approaches.^[3]

The safety profile of experimental treatments remains a paramount concern, especially when treating children. Phase I trials carefully monitor for any adverse effects, starting with low doses and gradually increasing them. Common side effects from immunosuppressive approaches may include increased infection risk, liver function changes, or blood cell count abnormalities. Researchers balance the potential benefits against these risks, always keeping patient safety as the top priority.^[3]

Most common treatment methods

• Anti-seizure medications
  • First-line treatment approach for controlling seizures, though often limited effectiveness in Rasmussen encephalitis
  • Multiple medications may be tried in various combinations and dosages
  • Most patients develop drug-resistant epilepsy that does not respond adequately to these medications alone
• Immunosuppressive therapy
  • Steroids to reduce brain inflammation and dampen immune system activity
  • Intravenous immunoglobulin (IVIG) infusions containing antibodies from healthy donors to modify abnormal immune responses
  • Treatment duration varies from months to years depending on patient response
  • Side effects may include increased infection risk, weight changes, and bone weakening with long-term steroid use
• Hemispherectomy surgery
  • Surgical disconnection or removal of the affected brain hemisphere
  • Most definitive treatment for achieving seizure control when medications fail
  • Modern techniques use functional hemispherectomy, which disconnects the hemisphere while leaving tissue in place
  • Results in permanent changes including one-sided weakness, vision loss, and potential speech difficulties if dominant hemisphere affected
  • Younger age at surgery may allow better functional compensation by the healthy hemisphere
• Rehabilitation therapy
  • Physical therapy to address weakness and mobility limitations
  • Occupational therapy to relearn daily activities and develop adaptive strategies
  • Speech therapy for language and communication difficulties
  • Intensive, long-term rehabilitation essential for maximizing function after surgery
• Experimental immunological treatments (in clinical trials)
  • Targeted therapies aimed at specific immune cells or pathways driving brain inflammation
  • Treatments to remove harmful autoantibodies from the bloodstream
  • Medications blocking T-cell activation or preventing immune cell entry into brain tissue
  • Available only through clinical trial participation at specialized epilepsy centers